Estimation of an optimal spectral band combination to evaluate skin disease treatment efficacy using multi-spectral images by Prigent, Sylvain et al.
Estimation of an optimal spectral band combination to
evaluate skin disease treatment efficacy using
multi-spectral images
Sylvain Prigent, Didier Zugaj, Xavier Descombes, Philippe Martel, Josiane
Zerubia
To cite this version:
Sylvain Prigent, Didier Zugaj, Xavier Descombes, Philippe Martel, Josiane Zerubia. Estimation
of an optimal spectral band combination to evaluate skin disease treatment efficacy using
multi-spectral images. IEEE International Conference on Image Processing (ICIP), Sep 2011,
Brussels, Belgium. 2011. <inria-00590694>
HAL Id: inria-00590694
https://hal.inria.fr/inria-00590694
Submitted on 4 May 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

ESTIMATION OF AN OPTIMAL SPECTRAL BAND COMBINATION TO EVALUATE SKIN
DISEASE TREATMENT EFFICACY USING MULTI-SPECTRAL IMAGES
Sylvain Prigent1, Didier Zugaj2, Xavier Descombes1, Philippe Martel2, Josiane Zerubia1
1EPI Ariana, INRIA/I3S, 2004 route des Lucioles, BP93, 06902 Sophia Antipolis, Cedex, France
Sylvain.Prigent@inria.fr, Xavier.Descombes@inria.fr, Josiane.Zerubia@inria.fr
2Galderma R&D, 2400 Route des Colles, BP87, 06902 Sophia-Antipolis, Cedex, France
Didier.Zugaj@galderma.com, Philippe.Martel@galderma.com
ABSTRACT
Clinical evaluation of skin treatments consists of two steps.
First, the degree of the disease is measured clinically on a
group of patients by dermatologists. Then, a statistical test is
used on obtained set of measures to determine the treatment
efficacy. In this paper, a method is proposed to automatically
measure the severity of skin hyperpigmentation. After a clas-
sification step, an objective function is designed in order to
obtain an optimal linear combination of bands defining the
severity criterion. Then a hypothesis test is deployed on this
combination to quantify treatment efficacy.
Index Terms— hypothesis tests, t-test, multispectral,
skin, hyperpigmentation
1. INTRODUCTION
One of the steps to evaluate the efficacy of a therapeutic so-
lution is to perform measurements on a series of patients who
received the studied treatment. In parallel another treatment
is tested on another group of people or on the same group of
patients on another skin area. This second treatment is the
reference one for the studied pathology or a placebo. In the
following we will use the word ‘vehicle’ to refer to this treat-
ment. For facial hyper-pigmentation, for each studied treat-
ment, a group of Ne patients receives the treatment on one
cheek and the vehicle on the other. To this end patients are
selected to have the same hyper-pigmentation severity on the
two cheeks. Then severity measurements are taken at differ-
ent time t along the treatment period. The standard method
for assessing effects of each treatment is to clinically scale the
disease severity of patients one by one with several dermatol-
ogists. This protocol is expensive, long and tedious. Further-
more it is especially prone to the variability of measures that
manifests as soon as these are performed by a human being.
To make the process more reliable, we propose an im-
age processing tool that quantifies automatically the disease
severity, and then, evaluates the treatment efficacy. To this
end, multi-spectral images are used. The process can be split-
ted in three steps: classification, severity measurement, sta-
tistical analysis of the results. To classify skin images of
hyper-pigmentation, several algorithms have been proposed
in the literature. The benchmark is the CIEL∗a∗b decom-
position [1] using color images. The L∗ component or the
ITA index [2] calculated with components L∗ and b∗ allows
to describe the pigmentation. To introduce the spectral infor-
mation, an algorithm proposed in [3] performs a source sep-
aration of the melanin and haemoglobin components from an
empirical analysis of their absorption. Methods based on im-
age processing techniques have been proposed in [4, 5] to per-
form a classification of healthy/pathological areas with multi-
spectral images.
Once the healthy and the pathological areas are classified, a
criterion has to be defined. This criterion computes the ‘dark-
ness’ of the skin. So, values of this criterion on both healthy
and pathological areas provide the severity measurements. To
define this criterion, only the spectral information is consid-
ered. It is then characterized by a vector λ such that the mea-
sure or darkness for pixel p is a linear combination of spectral
bands b:
Mp =
Nb∑
i=1
λibp,i, (1)
withMp the value of the criterion at pixel p,Nb the total num-
ber of bands in the multi-spectral image and λi the i
st coeffi-
cient of the linear combination λ = {λ1, ..., λNb}. Since the
severity on each patient at every measurement time t is calcu-
lated, a hypothesis test is deployed to measure if the severity
of the disease evolves significantly. The used test is a Stu-
dent test (t-test) [6] which quantifies the deviation of the mean
value between two distributions:
Zt,t0(t) =
X¯(t)− X¯(t0)√
σ2(t)
Ne
+ σ
2(t0)
Ne
, (2)
where X¯ and σ are the mean value and the standard devia-
tion of the two distributions respectively. In our application, a
distribution is a set of severity measurements on Ne patients.
The t-test is performed between a measure at time t and at the
baseline at the time t0. The null hypothesis is: “The mean
value of the distribution does not evolve from t0 to t”. If the
probability of false alarm (p-value) of the test is bellow 0.05
the null hypothesis is rejected. And, the lower the p-value,
the higher statistically is the deviation between the mean val-
ues of the two distributions, and the treatment is proved to be
efficient.
The paper is organised as follows. The second section
defines the normalization of the data to measure the disease
severity. The third section describes the objective function
proposed to find an optimum severity criterion per treatment.
Then the fourth section shows the obtained results and a com-
parison with the benchmark method.
2. DATA AND NORMALISATION
For each treatment, the data set of a study is composed of Ne
patients. Each patient has two treatments, the active prod-
uct and the vehicle, in two different areas. Thus there are
two multispectral images per patient. After classification of
healthy and pathological areas, an average spectrum is com-
puted for each region. Then, four spectra are obtained per pa-
tient and per time measurement: the healthy and pathological
spectra for the active product and for the vehicle. It comes that
two normalizations are needed to compute a severity value
from a criterion M . The first one is computed to normalize
the criterion measurement between healthy and pathological
area, and the second to normalize the measurement of the ac-
tive treatment by the vehicle. For the healthy/pathological
normalization there are two possibilities:
det = µMh − µMp (3)
and
det =
µMh − µMp
µMh
, (4)
where det denotes the severity of the disease for the patient e
at the measurement time t, and µMh and µMp are respectively
the average measurement of the darkness due to the criterion
M on the healthy and the pathological area respectively. The
equation (4) seems to be the best choice as it computes a de-
viation percentage of the pathological area with respect to the
healthy one. Nevertheless, the quotient introduces additive
noise. And as the two quantities µMh and µMp are homoge-
neous the normalization defined in equation (3) is preferred.
A second normalization is needed to compare the active
treatment and the vehicle. With the two images taken from the
same patient, there is again the two possible normalizations:
Det = d
e,A
t − d
e,V
t (5)
and
Det =
d
e,A
t − d
e,V
t
d
e,V
t
, (6)
where d
e,A
t and d
e,V
t are the severities measured at the time
t on the patient e on the image concerned by the active treat-
ment A, and the vehicle treatment V respectively. For the
same reason as above, the chosen normalization is the one of
equation (5). Then the final measurement of the severity ac-
cording to the studied treatment A compared to the reference
treatment V is:
Det = (µMh,A − µMp,A)− (µMh,V − µMp,V ) (7)
It can be noticed that this normalization is linear.
3. THE OBJECTIVE FUNCTION
To determine the severity Det of the patient e at the time t, a
criterion M is needed. In this section, we propose to define
an objective function to automatically estimate a criterionM
which is optimal to describe the treatment effects. If a treat-
ment has an effect, the deviation between the healthy and the
pathological areas decreases from the measurement times t to
t + dt. So, the best criterion will be the one which describes
this evolution with the finest scale. This is why, we design
an objective function that maximises both the deviation be-
tween healthy and pathological areas and the deviation of the
severity between time measurements:
∆
t−t0
[
1
Ne
Ne∑
e=1
[
D
e,M
t
]]
, (8)
where∆ is the differential between the initial time t0 and the
time t:
∆
t−t0
(Xt) = Xt0 −Xt. (9)
Since the objective is to maximize the deviation men-
tioned above for any measurement time t with respect to the
criterion M, the optimisation problem can be summarized by:
λˆ = argmax
λ
f(λ), (10)
where f is the objective function defined by:
f(λ) =
Nt∑
t=t0+dt
{
∆
t−t0
[
1
Ne
Ne∑
e=1
[
D
e,λ
t
]]}
(11)
where λ is the vector of coefficients defining the criterionM
andNt the number of time measures. To optimize the expres-
sion given by equation (10), the geometric simplex method is
used [7].
As the final value which quantifies the efficacy of a treat-
ment comes from a t-test one can propose to directly mini-
mize the p-value of the t-test. Nevertheless, the obtained spec-
trum will be correlated neither with the disease, non with the
treatment effect. That’s why we prefer not to do so.
4. EXPERIMENTAL RESULTS
4.1. The data set
The used data are 384 multispectral images taken from 48
patients during 3 months with one measure at the first visit
and one every month. Multi-spectral images contain 18 bands
in the visible and near infra-red spectra. The group of 48
patients is partitioned in 3 sub-groups of 16 patients. Each
sub-group corresponds to a specific tested treatment.
4.2. The treatments
The first treatment is the benchmark for skin pigmentation.
We will note it St. The two other treatments are from the same
product with two different doses. It is the tested product. The
two treatments will be called Ad2 and Ad3 where d stand for
dose and d2 < d3. A is written for Active. For the vehicle,
we use the active product with a low dose. We will note it
Ad1 with d1 < d2. Thus on the 3 groups we measure the
treatments St vs Ad1, Ad2 vs Ad1 and Ad3 vs Ad1.
4.3. The baseline
To analyse our method, we use the L∗ measure from the
CIEL∗a∗b. To obtain L∗, a spectral integration algorithm
projects the multi-spectral image to the XY Z colours space.
Then the transformation from XY Z space to CIEL∗a∗b
space allows us to extract the L∗ component.
4.4. The results
To avoid some bias due to the classification algorithm, patho-
logical and healthy areas are manually selected on each im-
age. Those areas are manually registered to be in correspon-
dence for each patient along the time sequence. Fig. 2 shows
the p-values obtained by the criterion computed with the op-
timization method. P-values below 0.05 are highlighted with
bold. The tested product with a d1 dose has an efficacy equiv-
alent to the standard treatment St. The null hypothesis of
the t-test is accepted with a high p-value for all the time se-
quences. When the dose of the product A increases, it effect
should increase and the higher the dose, the longer the effect.
The p-values of the t-test with the doses Ad2 and Ad3 de-
scribe well this behaviour. The criterion is adapted to quan-
tify hyper-pigmentation. Fig. 3 summarizes the p-value of
the same test but with the Luminance (L∗) as a criterion. This
test shows despite that St and Ad1 are equivalent, for higher
doses of A, the p-values do not reflect as well as previously
the treatment effect. Indeed, for the first measurement, after
one month, the effect is not visible; the p-values are above
0.05. Then, along the time sequence, even if the p-values for
the treatmentAd3 follow the expected variations, the p-values
variations for Ad2 are less coherent since they decrease under
the 0.05 threshold and then goes back above this threshold.
Thus, the conclusions are that the proposed criterion obtained
by optimisation is more sensitive to small variations than the
standard criterion L∗. To illustrate this sensitivity, we show
in Fig. 1 an example of the evolution of one patient that der-
matologists estimate cured at the end of the treatment. As
one can see, the measurement follows precisely the disease
evolution.
We propose now an interpretation of the criteria. The Lu-
minance is obtained from the component Y , by spectral inte-
gration on the multi-spectral images. As a result, L∗ in the
proposed process is equivalent to use the bands combination
Y shown in Fig. 5. Fig. 4 represents the λ coefficients de-
pending on the wavelength obtained by the proposed method.
All the obtained criteria have similar shapes but with small
variations due to there optimality to each treatment. If we
compare the obtained criterion curves with the absorbency
curves of melanin and haemoglobin (see Fig. 6) it can be no-
ticed that there is a link between the two. In fact, coefficients
of linear combinations are high, in absolute value, when the
deviation between haemoglobin and melanin absorbency is
high. This observation explains why the proposed method is
more efficient to describe the effect of a treatment. When L∗
measures only the middle of the spectrum, the objective func-
tion allows to select adapted spectral bands.
t0: severity = -8.84 t1: severity = -7.25
t2: severity = -3.06 t3: severity = -1.73
Fig. 1. Illustration of the treatment effect measurement with
the proposed method for the treatment Ad3.
t1 − t0 t2 − t0 t3 − t0
St vs Ad1 4.027 10
−1 6.545 10−1 2.867 10−1
Ad2 vs Ad1 1.158 10
−2
4.379 10−3 3.573 10−3
Ad3 vs Ad1 2.240 10
−2
5.282 10−3 5.458 10−4
Fig. 2. P-values obtained by minimizing the objective func-
tion on a spectrum from 400 to 700 nm.
t1 − t0 t2 − t0 t3 − t0
St vs Ad1 9.209 10
−1 5.977 10−1 9.07110−1
Ad2 vs Ad1 2.577 10
−1
1.478 10−2 8.625 10−2
Ad3 vs Ad1 1.072 10
−1
4.833 10−3 2.996 10−5
Fig. 3. P-values obtained with the Luminance (L∗) as the
darkness measure.
Fig. 4. Coefficients of bands computed by the minimisation
of the objective function for every couple of tested treatments.
Fig. 5. Coefficient of the linear combination of spectral band
to obtain the XYZ decomposition depending on the wave-
length.
Fig. 6. Absorbency curves of melanin and haemoglobin de-
pending on the wavelength.
5. CONCLUSION
In this paper, we have proposed a method to automatically
evaluate the efficacy of treatments with multi-spectral images.
The optimization of an objective function allows to find an op-
timal spectral metric for each tested treatment. We show that
such a metric gives a better analysis of the treatments than
the standard method. In future work, the spatial information
will be studied. In fact, only the spectral information of the
average value of a lesion has been exploited. The spatial dis-
tribution can give information on the disease and it evolution.
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